Suchergebnisse - (Standardsuche:issn:"1474-0338" OR issn:"1744-764X")

PubPharm (150)

41

Measuring drug burden in older adults with intellectual disabilities : Critical issues for consideration in finding the optimal measure to improve safety of medicines use

enthalten in: Expert opinion on drug safety | 2020

von O'Dwyer, M. | McCallion, P. | McCarron, M. | +2

42

Advanced analytics - translating registry science into regulatory actions

enthalten in: Expert opinion on drug safety | 2020

von Kemp, K. | Brun, N. | Quartarolo, J.

43

How can we manage the safety concerns associated with the increase in biologics for psoriasis?

enthalten in: Expert opinion on drug safety | 2020

von Silfvast-Kaiser, A. | Menter, M.

44

FDA Biosimilar Action Plan : could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars?

enthalten in: Expert opinion on drug safety | 2020

von Jordan, J. | Christl, L.

45

Selective inhibitors of nuclear export (SINEs) in myeloma : breakthrough or bust?

enthalten in: Expert opinion on drug safety | 2020

von Nishihori, T. | Baz, R.

46

Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity

enthalten in: Expert opinion on drug safety | 2019

von Bello, N.

47

Immunogenicity of infliximab and adalimumab

enthalten in: Expert opinion on drug safety | 2019

von Murdaca, G. | Negrini, S. | Greco, M. | +4

48

Should real-world evidence be incorporated into regulatory approvals?

enthalten in: Expert opinion on drug safety | 2018

von Spitzer, E. | Cannon, C. | Serruys, P.

CommentOn: N Engl J Med. 2016 Aug 4;375(5):454-63. - PMID 27518663

49

Things fall apart with hepatocellular carcinoma and direct-acting antivirals

enthalten in: Expert opinion on drug safety | 2018

von Kutala, B. | Valla, D. | Marcellin, P.

50

Cancer drugs and QT prolongation : weighing risk against benefit

enthalten in: Expert opinion on drug safety | 2017

von Menna, P. | Salvatorelli, E. | Minotti, G.